Price movement over the last 24 hours
Agilent Technologies Inc vs Standard Lithium Ltd — how do they compare? Agilent Technologies Inc trades at $128.2 (market cap $37.04B), while Standard Lithium Ltd trades at $2.47 (market cap $592.60M). The key difference: Agilent Technologies Inc is far larger — about 62.5× Standard Lithium Ltd's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| A | SLI | |
|---|---|---|
Market Cap | $37.04B | $592.60M |
Sector | Health | Basic Materials |
52-Week High | $157.20 | $5.65 |
52-Week Low | $110.24 | $2.29 |
Enterprise Value | $38.59B | $451.80M |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Standard Lithium (SLI) trades at $2.68, down 1.47% on the day, with a bearish technical signal from moving averages despite some bullish oscillators. The company reported a net loss of $48.40 million in 2025, with negative ROE and ROA, but maintains a P/B ratio of 1.8. Recent news highlights progress on its South West Arkansas lithium project, including a $225 million DOE grant and key construction contracts, positioning it for a final investment decision in 2026.
The investment case hinges on successful project execution and lithium market dynamics, with 100% analyst buy ratings signaling strong growth potential. Key risks include persistent negative cash flow from operations, high capital expenditures, and execution delays. Upside depends on timely project completion and favorable lithium pricing, while downside risks involve funding gaps and operational setbacks.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →